Primary prophylaxis for cryptococcosis with fluconazole in human immunodeficiency virus-infected patients with CD4 T-cell counts <100 Cells/μL and receiving antiretroviral therapy

Somnuek Sungkanuparph; Chutchaiwat Savetamornkul; Warisara Pattanapongpaiboon

doi:10.1093/cid/cix036

Primary prophylaxis for cryptococcosis with fluconazole in human immunodeficiency virus-infected patients with CD4 T-cell counts <100 Cells/μL and receiving antiretroviral therapy

Somnuek Sungkanuparph
, Chutchaiwat Savetamornkul
, Warisara Pattanapongpaiboon

Chakri Naruebodindra Medical Institute

Faculty of Medicine Ramathibodi Hospital, Mahidol University

Research output: Contribution to journal › Article › peer-review

11 Citations (Scopus)

Abstract

A prospective observational cohort study was conducted in 302 human immunodeficiency virus-infected patients who had a CD4 T-cell count <100 cells/μL and negative serum cryptococcal antigen initiating antiretroviral therapy in a resource-limited setting. During 2-year follow-up, there were no differences of survival rates and occurrences of newly diagnosed cryptococcosis between patients with and without fluconazole for primary prophylaxis of cryptococcosis.

Original language	English
Pages (from-to)	967-970
Number of pages	4
Journal	Clinical Infectious Diseases
Volume	64
Issue number	7
DOIs	https://doi.org/10.1093/cid/cix036
Publication status	Published - 1 Apr 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Antiretroviral therapy
Cryptococcosis
Fluconazole
HIV
Primary prophylaxis

Access to Document

10.1093/cid/cix036

Cite this

@article{358d29e687f7494d8347675fa6cfc54a,

title = "Primary prophylaxis for cryptococcosis with fluconazole in human immunodeficiency virus-infected patients with CD4 T-cell counts <100 Cells/μL and receiving antiretroviral therapy",

abstract = "A prospective observational cohort study was conducted in 302 human immunodeficiency virus-infected patients who had a CD4 T-cell count <100 cells/μL and negative serum cryptococcal antigen initiating antiretroviral therapy in a resource-limited setting. During 2-year follow-up, there were no differences of survival rates and occurrences of newly diagnosed cryptococcosis between patients with and without fluconazole for primary prophylaxis of cryptococcosis.",

keywords = "Antiretroviral therapy, Cryptococcosis, Fluconazole, HIV, Primary prophylaxis",

author = "Somnuek Sungkanuparph and Chutchaiwat Savetamornkul and Warisara Pattanapongpaiboon",

note = "Publisher Copyright: {\textcopyright} The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America.",

year = "2017",

month = apr,

day = "1",

doi = "10.1093/cid/cix036",

language = "English",

volume = "64",

pages = "967--970",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "7",

}

Primary prophylaxis for cryptococcosis with fluconazole in human immunodeficiency virus-infected patients with CD4 T-cell counts <100 Cells/μL and receiving antiretroviral therapy. / Sungkanuparph, Somnuek; Savetamornkul, Chutchaiwat; Pattanapongpaiboon, Warisara.
In: Clinical Infectious Diseases, Vol. 64, No. 7, 01.04.2017, p. 967-970.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Primary prophylaxis for cryptococcosis with fluconazole in human immunodeficiency virus-infected patients with CD4 T-cell counts <100 Cells/μL and receiving antiretroviral therapy

AU - Sungkanuparph, Somnuek

AU - Savetamornkul, Chutchaiwat

AU - Pattanapongpaiboon, Warisara

N1 - Publisher Copyright: © The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America.

PY - 2017/4/1

Y1 - 2017/4/1

N2 - A prospective observational cohort study was conducted in 302 human immunodeficiency virus-infected patients who had a CD4 T-cell count <100 cells/μL and negative serum cryptococcal antigen initiating antiretroviral therapy in a resource-limited setting. During 2-year follow-up, there were no differences of survival rates and occurrences of newly diagnosed cryptococcosis between patients with and without fluconazole for primary prophylaxis of cryptococcosis.

AB - A prospective observational cohort study was conducted in 302 human immunodeficiency virus-infected patients who had a CD4 T-cell count <100 cells/μL and negative serum cryptococcal antigen initiating antiretroviral therapy in a resource-limited setting. During 2-year follow-up, there were no differences of survival rates and occurrences of newly diagnosed cryptococcosis between patients with and without fluconazole for primary prophylaxis of cryptococcosis.

KW - Antiretroviral therapy

KW - Cryptococcosis

KW - Fluconazole

KW - HIV

KW - Primary prophylaxis

UR - https://www.scopus.com/pages/publications/85018277632

U2 - 10.1093/cid/cix036

DO - 10.1093/cid/cix036

M3 - Article

C2 - 28362939

AN - SCOPUS:85018277632

SN - 1058-4838

VL - 64

SP - 967

EP - 970

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 7

ER -

Primary prophylaxis for cryptococcosis with fluconazole in human immunodeficiency virus-infected patients with CD4 T-cell counts <100 Cells/μL and receiving antiretroviral therapy

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this